Abstract
Helicobacter pylori (H. pylori) is a gram negative, spiral, microaerophylic bacterium that infects the stomach of more than 50% of the human population worldwide. H. pylori is well recognized as a critical factor in the majority of patients with peptic ulcer disease and successful treatment results in cure of the disease. On the other hand, H. pylori infection has been associated with several extra-intestinal diseases such as hepatic encephalopathy. In this study, a triple treatment was used in management and eradication of H. pylori infection. We hypothesized that H. pylori infection and/or eradication treatment increased the releasing of α-glutathione S-transferase (α-GST). We also investigated whether α-GST is a more sensitive marker than aminotransferases (traditional liver function tests) for hepatocellular damage. However, we did not find any association between both H. pylori infection and eradication treatment and α-GST levels. According to our data, eradication treatment did not cause hepatocellular damage.
Keywords: Alkaline Phosphatase (AP), Chronic Liver Disease, Helicobacter pylori, Glutathione S-transferase immunoassay, Liver Function Tests
Current Drug Safety
Title: Release of α-Glutathione s-Transferase (α-GST) and Hepatocellular Damage Induced by Helicobacter pylori and Eradication Treatment
Volume: 2 Issue: 1
Author(s): Bensu Karahalil, Seyhan Yagar and Yasemin Ozin
Affiliation:
Keywords: Alkaline Phosphatase (AP), Chronic Liver Disease, Helicobacter pylori, Glutathione S-transferase immunoassay, Liver Function Tests
Abstract: Helicobacter pylori (H. pylori) is a gram negative, spiral, microaerophylic bacterium that infects the stomach of more than 50% of the human population worldwide. H. pylori is well recognized as a critical factor in the majority of patients with peptic ulcer disease and successful treatment results in cure of the disease. On the other hand, H. pylori infection has been associated with several extra-intestinal diseases such as hepatic encephalopathy. In this study, a triple treatment was used in management and eradication of H. pylori infection. We hypothesized that H. pylori infection and/or eradication treatment increased the releasing of α-glutathione S-transferase (α-GST). We also investigated whether α-GST is a more sensitive marker than aminotransferases (traditional liver function tests) for hepatocellular damage. However, we did not find any association between both H. pylori infection and eradication treatment and α-GST levels. According to our data, eradication treatment did not cause hepatocellular damage.
Export Options
About this article
Cite this article as:
Karahalil Bensu, Yagar Seyhan and Ozin Yasemin, Release of α-Glutathione s-Transferase (α-GST) and Hepatocellular Damage Induced by Helicobacter pylori and Eradication Treatment, Current Drug Safety 2007; 2 (1) . https://dx.doi.org/10.2174/157488607779315426
DOI https://dx.doi.org/10.2174/157488607779315426 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Epigenetic Targets in Lymphoproliferative Disorders
Current Cancer Drug Targets N-Terminal-Dependent Protein Degradation and Targeting Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Comparison with Naloxone of Two Dynorphin a Analogues with K- and δ-Opioid Antagonist Activity
Medicinal Chemistry Protein Secretome Analysis of Evolving and Responding Tumor Ecosystems
Current Proteomics The Importance of Lamivudine Therapy in Liver Cirrhosis Patients Related HBV with Advanced Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion Chemotherapy
Clinical Cancer Drugs Multifuntional Nanoparticles: Preparation and Applications in Biomedicine and in Non-Invasive Bioimaging
Recent Patents on Nanotechnology Nitric Oxide in Health and Disease from the Point of View of the Otorhinolaryngologist
Current Pharmaceutical Design A Review on Electrochemical Sensing of Cancer Biomarkers Based on Nanomaterial - Modified Systems
Current Analytical Chemistry Anticarcinogenic Actions of Tributyrin, A Butyric Acid Prodrug
Current Drug Targets Revisiting Non-Cancer Drugs for Cancer Therapy
Current Topics in Medicinal Chemistry Recent Advances in Magnetic Nanoparticle-based Molecular Probes for Hepatocellular Carcinoma Diagnosis and Therapy
Current Pharmaceutical Design Chromatin Structure and Epigenetics of Tumour Cells: A Review
Cardiovascular & Hematological Disorders-Drug Targets Harnessing Impaired Energy Metabolism in Cancer Cell: Small Molecule- Mediated Ways to Regulate Tumorigenesis
Anti-Cancer Agents in Medicinal Chemistry Role of Nitric Oxide in the Modulation of Angiogenesis
Current Pharmaceutical Design Melanoma Immunotherapy: Past, Present, and Future
Current Pharmaceutical Design Crosstalk Between The Immune Receptors and Gut Microbiota
Current Protein & Peptide Science Cancer and Phase II Drug-Metabolizing Enzymes
Current Drug Metabolism Latest Advances in OBOC Peptide Libraries. Improvements in Screening Strategies and Enlarging the Family From Linear to Cyclic Libraries
Current Pharmaceutical Biotechnology Sensory-Motor Integration in the Medial Medulla
Current Neuropharmacology Subject Index To Volume 8
Current Pharmaceutical Design